Adicet Bio Appoints Nick Harvey as Chief Financial Officer

Chartwell Partners is pleased to announce the recruitment of Nick Harvey as Chief Financial Officer for Adicet Bio, a public biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Mr. Harvey joins Adicet most recently from Centrexion Therapeutics, a privately held biotechnology company, where he served as Executive Vice President and Chief Financial Officer. Previously, he served as the Chief Financial Officer of Radius Health where he helped successfully complete its initial public offering and transition from a research and development stage company to a commercial organization. For more information, please visit: